| Expression pattern: |
UP |
| Associated gene: |
TAGLN2, Ago2, cyclinD1, GLS1 |
| Associated microRNA: |
miR•296•5p |
| Biological function: |
circ•BICD2 acts as an oncogenic circRNA in OSCC; knockdown inhibits cell viability, colony formation, migration, invasion, S-phase progression, glutamine metabolism and tumor growth, and promotes apoptosis. |
| Molecular mechanism: |
circ•BICD2 directly targets miR•296•5p and regulates TAGLN2 expression through the miR•296•5p/TAGLN2 molecular axis, thereby affecting glutamine metabolism and malignant biological behavior in OSCC cells. |
| Biological pathway or process: |
proliferation (promotes); migration (promotes); invasion (promotes); apoptosis (inhibits); cell cycle (promotes); glutaminolysis (promotes); ceRNA regulation (other) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Clinical Sample Validation; Bioinformatics Analysis; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Cell Cycle Assay; Wound Healing Assay; Transwell Assay; Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model |
| Clinical significance: |
circ•BICD2 may be a potential therapeutic target for OSCC. |
| Description: |
circ•BICD2 is up-regulated in OSCC tissues and cells and functions as an oncogenic circRNA. Its knockdown suppresses OSCC cell proliferation, migration, invasion, cell-cycle progression, glutamine metabolism and xenograft tumor growth while promoting apoptosis. Mechanistically, circ•BICD2 targets miR•296•5p and regulates TAGLN2 expression through the miR•296•5p/TAGLN2 axis, suggesting potential therapeutic relevance in OSCC. |
| Confidence score: |
0.8006 |